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Abstract 
 
Introduction: Kidney and pancreas transplant recipients risk thromboembolism and lower limb 
edema due to immobility and fluid shift after surgery. Intermittent pneumatic compression (IPC) 
devices + Thromboembolic deterrent (TED stockings) are used to mitigate these risks. However, 
they risk peroneal nerve injury, discomfort, excessive heat and sweating under the cuffs. The 
 
Geko
TM
 device, is an internally powered calf neuromuscular stimulator, shown to have 
beneficial effects in improving blood flow and skin capillary perfusion. Its role in transplantation 
has not previously been assessed. Our objective was to prospectively evaluate the effects of 
IPC+TED stocking and the Geko
TM
 devices on lower limb edema in renal and pancreatic 
transplant patients. 
 
Methods: In a prospective, randomized, and controlled, single-center study we enrolled patients 
randomly to wear IPC + TED stockings or the Geko
TM
 device post-operatively until day 6 after 
kidney or kidney and pancreas transplant surgery. 
 
Results: We observed a significant reduction in lower limb edema, increased urine output, and a 
significantly improved patient satisfaction rate with the use of the Geko
TM
 device. 
Conclusion: The use of the Geko
TM
 device in the immediate post-operative period leads to an 
improvement in lower limb edema in kidney and pancreas transplant recipients compared to 
IPC+TED stockings. 
 
 
 
Keywords: 
 
Geko
TM
 device (neuromuscular stimulator), Intermittent pneumatic compression (IPC), 
Thromboembolic deterrent (TED stockings), Edema, kidney and pancreas transplant. 
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Chapter 1 
 
 
 
 
1.1 Introduction 
 
Kidney Transplantation and Pancreas Transplantation 
 
Kidney transplantation is the most appropriate solution to individuals suffering from end-
stage renal disease (ESRD). However, only a few adult patients with ESRD are referred for 
transplantation evaluation, with a 5-year mortality rate of 70% in dialysis (Matas, et.al. 2014). 
Significant advancements in long-term and early graft survival and function have led to 
continued affordability and efficiency of kidney transplantation to dialysis. Over 500,000 
transplants have been performed in the U.S, with 200,000 patients living with a functional 
kidney transplant as of 2015. However, an additional 151,000 patients are currently in the kidney 
transplant waiting list (UNOS, 2015) Additionally, the number of people being treated for kidney 
failure in Canada in 2010 was 39, 352 with 41% (16,164) having a functional transplant. 
According to Canadian Organ Replacement Register (CORR), cases if kidney transplant are on 
the rise with 1267 transplants conducted in 2013 alone as compared to 1196 and 1245 in 2011 
and 2012. 
 
Renal transplantation offers less cardiovascular events (Brunkhorst, et al., 2003; Ward, 
2000), less hospitalization, decreased mortality (Chauveau, et al., 2009; Sezer, et al., 2004) and 
morbidity, and better quality of life (Baiardi, et al., 2003). The treatment costs for transplant 
patients are less compared to cumulative dialysis costs by at least a third (Bruno, et al., 2003). 
However, missing dialysis sessions comes with serious life threatening consequences among 
them pulmonary edema, hyperkalemia leading to arrhythmias, or coma related uremic 
encephalopathy. 
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Dialysis fails to reduce other ESRD complications like bleeding tendency, immune 
suppression, chronic anemia, and metabolic bone disease despite being a mandatory survival 
necessity to the patients. 
 
However, there are high risks especially to patients with much comorbidity that can limit 
the kidney transplantation operation. There is a long list of surgical complications with a 
significant number of them being serious with considerable mortality or morbidity risks. Other 
risk factors include the immunosuppressing medications requirements whose side effects range 
from infections, coronary artery disease, and cancers. 
 
Pancreas transplantation is carried out to solve insulin-dependency in patients suffering 
from type 1 diabetes in addition to eliminating injected insulin dependence (Wiseman AC, 
2010). Approximately 1.25 million people suffered from type 1-diabetes in the U.S as of 2012. 
Pancreas transplantation, concurrently with a kidney graft was first successfully performed in 
1966 (Sutherland, et al., April 2001). Currently, simultaneous performance of pancreas and 
kidney transplantations and from the same deceased donor stands at 75% of all pancreas 
transplants performed in North America. Additionally, pancreas-after-kidney transplantation 
rates stand at 15% and are performed from either a deceased or a living donor. However, single 
pancreas-after-kidney transplantation hold the remaining 10% with the patients who having 
normal kidney function, but with very labile life-threatening hypoglycemic unawareness related 
to problematic diabetes (Morath et al., 2008). 
 
Successful pancreas transplantation will lead to a normoglycemia and reduced 
dependence on insulin by reversing the diabetic alterations seen as a result of diabetic 
nephropathy in recipient patients’ native kidneys. Additionally, it prevents recurrent diabetic 
nephropathy in pancreas-kidney transplantation patients, while improving the length and quality 
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of life through reversing the peripheral sensory neuropathy and stabilizing the advanced diabetic 
retinopathy (Kuffman, 2001). The 1 year patient survival rates are 95%, 91%, and 86%, for 
kidney, pancreas, and kidney-pancreas transplant, respectively. Pancreas addition improves the 
long-term survival patient and kidney graft survival to patients with diabetes (McCullough et al., 
2009). The average 1-year pancreas graft survival rate for pancreas-after-kidney transplant 
recipients or a lone pancreas transplant is 78-83% while that of the kidney is 77-82%. 
 
 
1.2 Kidney transplantation complications (medical and surgical) 
 
Patients who undergo renal transplantation may experience both surgical and medical 
complications after kidney transplantation surgery. It is therefore necessary to screen both 
recipient and the donor according to the U. S Centers for Disease Control and Prevention (CDC) 
standards in addition to United Network for Organ Sharing (UNOS), as well as local transplant 
work-up guidelines. 
 
 
1.2.1 Surgical Complications 
 
Being a major operation, kidney transplantation poses major organ operations 
complications. Surgical complications were a major cause of kidney graft loss in the past with 
20% occurrence between 1960 and 1980. However, their frequency has dropped significantly 
due to technological and procedure advancements (Botto V, 1993; Hernandez D, 2006). As 
expected, surgical complications that arise after kidney transplant increase morbidity, 
hospitalization and costs despite the improvements (Humar A, 2005). Many of these risks are 
accentuated by factors such as increasing age of the recipient, obesity and concomitant vascular 
disease (Hernandez D, 2005). 
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The following is a list of some of the common complications of renal transplantation: 
 
 
 
 
1.2.1a Wound Infection and Hernias 
 
Wound infections contribute significantly to postoperative morbidity after renal 
transplantation (Lynch, 2009), likely due to the obligate medication regimented 
immunosuppression apart from the routine risk of surgical site infections arising from standard 
procedures. 
 
Infection rates are high during the first year after transplantation (Sousa SR, 2010) and up 
to 25% of these patients require radiological or surgical intervention and with wound infections 
ranging from 10 to 27% (Røine E, 2010; Khoury JA, 2005; Fortun J,2010). Impaired wound 
healing after kidney transplantation has various risk factors such as dialysis pre transplantation, a 
body mass index >30, post transplantation plasmapheresis, use of thymoglobulin as induction 
therapy or in its use in acute rejection, mycophenolate mofetil-induced immunosuppression, use 
of sirolimus for maintaining immunosuppression, recipients older than 60 years, and delayed 
graft function (Fortun J,2010; Santangelo M,2009). Additionally, incisional hernias are a major 
source of postoperative morbidity as most require surgical repair at some point. However, hernia 
formation is more prevalent in males, older people, those participating in heavy physical labor, 
and previous surgery (Mazzucchi E, 2001; Knight RJ 2007). Additionally, the estimates of post 
kidney transplantation hernia formation range from 1.6 – 18%. 
 
1.2.1b Vascular Complications 
 
There might be early kidney transplant loss due to renal artery acute thrombosis which 
remains a devastating complication, with chances of occurrence ranging between 0.2- 7.5%. 
Despite being uncommon, arterial thrombosis in the early postoperative period creates surgical 
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emergency which should not be conducted if previously established diuresis ceases suddenly. 
Arterial thrombosis has often been attributed to technical factors encountered during the vascular 
anastomosis, use of atheromatous arteries, hypercoagulability, end-to end anastomosis and 
allograft malposition (Keller, 2012; Knechtle, 2008). 
 
Despite being uncommon, renal vein thrombosis is a serious complication with incidence 
rates ranging from 0.9 - 4.5% and usually occurs a few days after transplantation and may lead to 
graft loss (Giustacchini P, 2002). Given that the transplanted kidney has no collateral circulation, 
venous stasis and thromboembolism often causes acute graft dysfunction. 
 
Renal artery stenosis mainly affects 3–24 months post-transplant (Bruno S, 2004) and is 
common to up to 12% of transplant recipients with hypertension (Audard, 2006). Transplant 
renal artery stenosis risk factors include delayed transplant function, cytomegalovirus infection, 
organ procurement complications, and poor surgical techniques. 
 
Another devastating complication of renal transplantation is renal arterial pseudo-
aneurysm formation which occurs in approximately 1% of renal transplants. One of the causes is 
injury to the renal artery during procurement or preservation, excessive stripping of the artery 
and its vasa vasorum which cause ischemic damage, faulty suture technique, in addition to 
external traumatic injury. Additionally, it can result from an infected arterial anastomotic suture 
line from mycotic aneurysm either from bacterial or fungal pathogens (Dalla Valle, 2005; 
Orlando, 2009; Osman, 2009). 
 
1.2.1c Lymphocele and Hemorrhage 
 
Lymphocele is the accumulation of lymphatic fluid in the retroperitoneal space next to 
the graft and can originate either from the recipient iliac lymphatic vessels or from the allograft 
renal hilum. The average lymphocele occurrence rate ranges from 0.6 to 16% (Adani, Baccarani. 
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2007; Zargar- Shoshtari, Soleimani. 2008; Iwan-Zietek, Zietek. 2009). Inadequate ligation of the 
delicate system of lymph vessels overlying the iliac vessels, or present in the hilum, attribute to 
the etiology. 
 
Unrecognized vessel in the donor renal hilum or surface; allograft vascular suture line 
disruption; inadequate preparation of the graft bed and presence of poorly ligated pelvic or 
epigastric vessels; or abnormal recipient coagulation mechanisms can also cause acute 
postoperative hemorrhage. Requirement of hemodialysis often accompanied by anticoagulation 
in the immediate postoperative period may also increase postoperative hemorrhage (Rabrenovic, 
2007). 
 
 
1.2.1d Urine Leak and Ureteric Obstruction 
 
Urine leak or urinoma complications occur in up to 3% of patients undergoing kidney 
transplantation (O'Neill CW, 2002). The condition is observable in the first days/weeks after 
kidney transplant especially after the removal of urinary catheter. The main cause is leakage at 
the site of anastomosis of the ureterovesicle anastomosis as a result of poor surgical technique or 
ureteric necrosis. Ureteric necrosis is often caused by over-enthusiastic adventitial tissue 
stripping around the ureter while preparing for implantation. 
 
Ureteral obstruction at some time after surgery will develop in approximately 1%–4.5% 
of renal transplant recipients (E.H. Streeter, 2002; J. Lempinen,2015) and nearly 90% probability 
is due to ureteral devascularization cases which leads to intrinsic stricture formation (S. 
Kumar,2014). Major causes of obstruction during the early postoperative i.e. during a 3 months’ 
period include technical errors during the ureteroneocystostomy, collecting system hematoma; 
extrinsic compression such as hematoma, lymphocele, and abscess; kinking of a redundant 
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ureter, a renal stone mistakenly transplanted with the kidney, and anastomotic edema. Late 
obstruction during the period beyond 3 months usually results from ureteral ischemia. 
Additionally, vasculitis may also occur. There are a variety of treatment options for these 
complications ranging from radiological, endoscopic to open surgical approaches. A new 
systemic review showed that open management has higher success rates and fewer complications 
than endourological management as a primary and secondary treatment for post-transplant distal 
ureteric strictures (Sener et al.,2016). 
 
1.2.2 Medical Complications 
 
Graft loss arising from rejection has significantly been reduced as a result of better 
immunological cross matching techniques and selection of induction immunosuppression after 
renal transplantation, all of which have increased the success rates of long term graft function. 
However, more elderly patients and the number of patients with multiple co-morbidities 
receiving renal allografts are on the rise, thus consequently their risk of medical complications 
and transplant-related spectrum of complications as a result of the immunosuppression, their 
underlying disease or the previous uraemia state are a concern. 
 
Rejection is most commonly due to T cell mediated processes but can also be attributable 
to B-cell mediated rejection and is dependent upon induction regimens, tissue cross matching 
and patient alloreactivity. 
 
Acute cellular rejection occurs in a 25% of all patients normally within the first 1-3 
weeks which can extend to 3 months. Signs include fluid retention, high blood pressure, and 
rapid increase in serum creatinine. Lastly, chronic rejection is observed late after transplantation 
and is associated with hypertension, excretion of protein in urine and gradual rise in serum 
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creatinine. Unlike other forms of rejection, chronic rejection is inevitable and cannot be acutely 
remedied with immunosuppressive therapies. 
 
There is a lower risk of fatal and nonfatal cardiovascular events in transplant recipients in 
relation to wait-listed patients on dialysis (Lentine KL, 2005; Meier-Kriesch, 2004). However, 
they face a much higher risk compared with the general population (Jardine, 2011). 
Cardiovascular disease is one of the common risks and the most common cause of death in graft 
function after transplant patients and accounts for 30 percent of graft loss from death overall, 
with early after transplant facing the highest risk. On the other hand, hypertension and 
transplantation are closely related and the risk of their association may promote impaired graft 
and overall survival (Kasiske, 2004). High blood pressure frequently occurs early after kidney 
transplantation due to saline loading and its interaction with initial high-dose 
immunosuppression when they are present. However, it is observed in 50–80% of transplanted 
patients since calcineurin inhibitors started being used (Vella, 2009). 
 
New-onset diabetes mellitus (NODAT) is a serious long-term transplantation 
complication known since the past and various clinical studies demonstrate that it is associated 
with low survival rates in both patient and graft. A research reported that every patient with pre-
transplantation diabetes and 87% of those without it had evidence of hyperglycemia (bedside 
glucose above 200 mg/dL or physician-instituted insulin therapy) during recovery or initial 
hospitalization post transplantation (Chakkera, 2009). NODAT development is associated with a 
number of factors including deceased kidney donor, age of the recipient, presence of hepatitis C, 
polycystic kidney disease (ADPKD), rejection, and using tacrolimus in place of cyclosporine. 
NODAT reduction is associated with incidence of withdrawal or avoidance of steroid and statin 
therapy (Pascual, 2009). 
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Long-term risk of malignancy overshadows improvements in renal recipient and graft 
survival rates in transplantation. The nature and intensity of immunotherapy and its relationship 
to subsequent malignancy has been extensively reviewed (Vella, 2008). However, the most 
common malignancies in adult kidney transplant recipients are skin and lip carcinomas which, by 
far, account for between 40% and 53% of the total transplant patient malignancies (Kasiske BL, 
2000). 
 
Depression is another complication which occurs early after transplantation in the kidney 
transplant population and has been associated with the use of prednisone immunosuppression. It 
is occurring in over 45% of recipients. With one particular study reporting a suicide rate of 24 
per 100,000 patient-years in kidney transplant recipients which is 84% higher than the general 
population (Kurella et al., 2005). 
 
Many post renal transplantation infections remain a significant cause of morbidity and 
mortality among kidney transplantation recipients. Additionally, augmented immunosuppression 
may occur after graft dysfunction or chronic rejection consequently increasing the risk for viral 
infections. Infections are the second to cardiovascular events in the common causes of death in 
renal transplant recipients despite prophylactic therapy against common pathogens. The U.S. 
Renal Data System (USRDS) indicate that infections occurred at a rate of 45 per 100 patient-
years in initial 3 years’ post transplantation (Snyder et al., 2009). 
 
 
1.3 Lower Limb Edema after Kidney Transplantation 
 
Edema is defined as the swelling that is caused by accumulation of fluid in the spaces 
around various tissues and can occur nearly anywhere in the body after kidney transplantation. 
Some of the most common forms of edema include the peripheral edema which affects the upper 
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or lower limbs, intraabdominal ascites, pleural effusion around the lungs and lastly pulmonary 
edema. Peripheral edema is uncomfortable to most patients and may lead to more severe 
conditions after kidney transplantation. (Richard, 2016). 
 
1.3.1 Pathophysiology 
 
Water and solutes of low molecular weight such as salts move between the intravascular 
and interstitial under the primary control of plasma colloid osmotic pressure and the opposing 
effect of vascular hydrostatic pressure. The outflow of these fluids from the microcirculation 
arteriolar end into the interstitium is nearly balance to inflow at the venular end. However, the 
interstitium may be left with a small residual amount of fluid which drains into the lymphatic 
vessels to return to the bloodstream through the thoracic duct (Dongaonkar et al., 2009) 
(Figure1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Either increased capillary pressure, diminished colloid osmotic pressure or inadequate 
lymphatic drainage can result in an abnormally increased interstitial fluid i.e. edema. 
 
Source: www.medicinehack.com/2012/10/edema-definition-pathophysiology-causes.html?m=1 
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1.3.2 Causes of Edema after Kidney Transplantation 
 
Lower limb edema after a kidney transplant is commonly experienced by post- kidney 
transplant surgery patients. Most patients experience edema at their ankles and legs after kidney 
transplant because they are exposed to large fluid volume infusions. After a successful kidney 
transplant, it takes the patient’s body time to adjust to the new kidney. Also, the lower limb 
edema, which is usually located on the side similar to the renal transplant, results from the action 
of renal transplant through the compression of iliac vein in combination with the collection of 
peri-renal fluid and potential obstruction from ligated iliac lymphatic trunks. 
 
1.4 Intermittent Pneumatic Compression Device and Compression Stocking (And Their 
 
Role in Deep Vein Thrombosis and Lower Limb Edema) 
 
Deep vein thrombosis prophylaxis mechanical methods have gained extensive acceptance 
over the last three decades for surgical patients and are becoming more popular across various 
geographical locations (Prandoni, 2004). However, intermittent compression devices exist in a 
great range of forms, but they lack broad understanding of the relative efficiency of specific 
systems. However, all systems depend on periodical deflation and inflation of a pump in form of 
air bladders within cuffs that are wrapped around the limb. The cuffs can either wrap the calf, the 
feet, or a whole limb and will inflate uniformly or sequentially according to the specified 
pressures that determine if rapid or moderate inflation rates are to be followed. These different 
attributes naturally have cost implications, and, more importantly, possible influences on patient 
compliance, which is critical with these methods of prophylaxis; the longer they are used, the 
better the protection. Therefore, it is important, when choosing a system for patient care, to 
understand the hemodynamic reasoning behind its attributes, the validity of those claims, and 
any medical implications, before cost and compliance are considered (Geerts, 2001). 
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The cuff and pump borrow innovations and design from fluid dynamics and blood flow 
analysis. The link between DVT and blood flow velocity and the comprehensive studies in the 
field date a century and a half back since the ages of Rudolf Virchow who initially defined blood 
flow velocity and the subsequent pulmonary embolism risk, in addition to offering a description 
of the causal factors afterwards. Additionally, the hypercoagulability, vessel damage, and stasis 
are still among the recognized thrombogenesis influences. However, stasis prevention was the 
ultimate lead to the intermittent compression for prophylaxis of the development of deep vein 
thrombosis (Wicklin, 2011). 
 
The main purpose of all intermittent compression systems is to squeeze blood from the 
underlying deep veins that will be displaced proximally assuming that the valves are competent. 
The veins refill during cuff deflation and the intermittent nature of the system and adequate 
supply will guarantee periodic blood flow through the deep veins. Doppler ultrasound easily 
determines the peak velocity, percentage augmentation, and duration; which are pulse of flow 
properties, are a source of competition between compression devices. 
 
A study by Wilson, et al. (2005) demonstrates the effectiveness of intermittent pneumatic 
compression (IPC) devices as thromboprophylactic devices. The study further revealed that IPC 
and TED stockings are important in edema and deep vein thrombosis management. Most 
pneumatic compression devices are designed in form of plastic sleeves enclosing the whole limb 
or foot which leads to compliance and comfort challenges (Comerota, Katz, & White, 1992). In 
addition to requiring a pump, the device weight, size, an external power source, and attached 
tubing also limit the IPC devices application (Wilson et al., 2005). 
 
Imaging studies demonstrate a rate between 4.5% and 43% despite the risk for clinically 
relevant thrombosis in a cast not being established clearly the past literature studies in which 
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case prophylaxis must be considered (Testroote, Stigter, de Visser, and Janzing, 2008). However, 
the most appropriate prophylaxis is yet to be established and a chemical agent may have to be 
applied over time in the plaster especially when there are signs of effect (Roberts, 2012). 
Mechanical methods would be more appropriate for patients with a risk of bleeding, especially 
soon after surgery or injury; on the other hand, traditional mechanical methods are not practical 
for patients in a plaster cast. 
 
Most modern intermittent devices pump blood from lower-extremity vessels in an 
automated mode with sequentially deliverance of compression up the limb, producing a wavelike 
milking effect to evacuate leg veins with regular compression cycle. A microprocessor controls 
air pressure and direction into segmental diaphragms secured around the leg for a fixed period of 
time (Kendall Healthcare Products Company, 1995). However, various reports consistently show 
that all IPC devices produce changes in femoral vein velocity. The typical maximum velocities 
achieved following the compression of calf and/or thigh at pressures around 40 mm Hg would be 
35–60 cm/s with maximum compression velocity compared with maximum velocity stabilizing 
at a range of 50–250% (Whitelaw et al., 2001) (Figure 2). 
 
Notably, the venous blood flow is variable and resting blood flow in the femoral vein 
varies between different people (Fronek et al., 2001) in addition to varying in a single subject 
over time as a result of natural limb inflow fluctuations (Lewis et al., 1986). The flow pattern 
will change with respect to the particular physiology and posture. However, breathing and the 
cardiac cycle modulate the flow to differing extents (Abu-Yousef et al., 1997). In addition, 
venous blood pressure varies chronologically which means that the velocity results from a 
particular pump and for a particular individual will also vary over time. 
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Improper fitting, inappropriate use of device, peroneal nerve injury, discomfort, excessive 
heat and sweating under the inflatable cuffs are some of the limitations of IPC devices. 
Furthermore, the device size, weight and external power source requirements contribute to poor 
compliance and fall risks due to attached chords which limit the efficacy of IPC devices (Wright 
et al., 2010). 
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FIGURE 2: Venous blood flow velocity in the femoral vein during compression by a two-
bladder graduated sequential thigh-length cuff (velocity [cm/s] vs. time [1 second per vertical 
dotted line]. Source: www.medscape.com 
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1.5 Compression Stockings 
 
These are specialized hosiery wearable stockings which help in prevention of, and 
reduction of further progression of venous disorders such as phlebitis, edema, and venous 
thrombosis (Miramar, 2004). These elastic garments are worn around the lower limb with an 
intention to compress it thus reducing the diameter of distended veins while simultaneously 
raising venous blood flow velocity and valve effectiveness. Compression therapy helps in 
decrease venous pressure and consequently preventing venous stasis and venous wall 
impairments while relieving pain and perceived weight of the legs (Meissner et al., 2007). They 
are tightest at the ankles with gradual constrictive reduction toward the knees and thighs. They 
force circulating blood through narrower channels through compressing the surface veins, 
arteries and muscles. Consequently, the pressure of the arteries carrying blood to the heart 
increases than that of blood flowing through the limbs. This increases the blood flow to the heart. 
Compression stockings exist in two forms; anti-embolism and gradient. 
 
Gradient Compression Stockings 
 
Gradient compression stockings are designed to reduce and manage impaired 
"musculovenous pump" performance which results from incompetent limb vein valves. They are 
designed in such a way that the compression level is the highest around the ankle with gradual 
decrease towards the top of the hose. They are recommended for people prone to leg edema, 
blood clots, and blood pooling in the lower limbs and feet as a result of prolonged sitting or 
inactivity periods. These stockings often address lymphedema, thrombosis, cellulitis, and other 
post-transplant complications (Blattler et al., 2008). 
 
Prior to using compression stocking cautionary steps need to be taken. A patient's ankle 
brachial pressure index (ABPI) must be greater than 1.0 per limb; otherwise the stockings may 
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interfere with the patient's arterial flow. The ankle brachial pressure indicates the level of 
unobstruction on the patient's limbs’ arteries (Marston et al., 2003). It is also necessary that 
compression stockings are properly sized in relation to limb size. The compression should 
gradually reduce from the highest compression at the ankle’s lower section to ultimately obtain a 
 
70% reduction of pressure just below the knee (Partsch et al., 2008). 
 
Anti-Embolism Compression Stockings 
 
These stockings are commonly referred to as Thromboembolism Deterrent (TED) 
stockings hose that are used for venous and lymphatic drainage support and that are intended to 
exert mild pressure on lower limbs to prevent blood clotting and often support the venous and 
lymphatic drainage systems within the lower limbs. Anti-embolism stockings exert a distributed 
compression force at the ankle and up the leg in the same way as gradient compression 
stockings. When combined with the calf’s muscle pump effect, this compression aids in 
circulating blood and lymph fluid through the lower limbs especially in non-ambulatory patients 
(Blattler et al., 2008). The compression degrees or levels are divided into Mild <20 mmHg, 
 
Moderate ≥20–40 mmHg, Strong ≥40–60 mmHg, And Very strong >60 mmHg (Partsch et al., 
2008). 
 
Table 1 below gives a general guide to the recommended amount of compression for 
various indications. Patient factors and the underlying disease process determine the ideal sub-
bandage pressure (mmHg) required for therapy. The stocking pressure is directly related to the 
number of layers applied the tension while indirectly related to the leg circumference and the 
bandage width (Thomas S, 2003). The application technique and the sub-bandage pressure are 
dependent on both the skill of the person applying the bandage and the bandage type. The final 
sub-bandage pressure, however, depends on the tension of application. 
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Degree of  
Compression Indication (Use) 
  
<20 mmHg   Prevention of deep vein thrombosis (graduated compression stocking) 
   Treatment of mild edema 
   Relief for tired, aching legs (occupational leg symptoms) 
  
20–30 mmHg   Treatment of mild varicose veins 
   Treatment of mild to moderate edema 
   Relieving fatigue after long-haul flights (>4 hours, high-risk patients for 
 deep vein thrombosis) 
   Treatment of varicose veins during and after pregnancy 
  
30–40 mmHg   Treatment of venous ulcers (including healed ulcers) 
   Treatment of deep vein thrombosis 
   Treatment of superficial thrombophlebitis 
   Following venous surgery and sclerotherapy 
   Treatment of varicose veins with severe edema and/or skin changes 
   Treatment of post-thrombotic syndrome 
   Treatment of mild lymphedema 
  
>40 mmHg   Treatment of severe lymphedema 
   Treatment of severe chronic venous insufficiency 
  
Table 1: Guide to recommended compression for various indications. 
 
Adopted from www.nps.org.australian-prescriber/articles/compression-therapy-for-venous- 
 
disease 
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If the calf muscle pump is ineffective or ankle mobility is limited, then the effect of compression 
therapy is limited irrespective of the compression method. The variable ankle mobility and calf 
muscle function have a likelihood of accounting for much of the variability in the compression 
therapy success (Bolton L, 2008). 
 
 
1.6 Summary 
 
Numerous currently available systems can utilize a wide range of various compression 
sequences and techniques in despite intermittent pneumatic compression (IPC) being is an 
established method of deep vein thrombosis (DVT) prophylaxis and edema treatment in the legs. 
However, overall system performance and the physiological effects of specific variables should 
be critically and objectively analyzed in order to make suitable choices that will provide the 
maximum patient protection. 
 
 
1.7 Neuromuscular Stimulators and Their Role in Deep Vein Thrombosis Prevention in 
 
Lower Limb Edema 
 
National Institute of Clinical Excellence (NICE) has approved the NeuroMuscular 
ElectroStimulation (NMES) for prophylaxis against deep vein thrombosis (DVT). According to 
various credible evidences, neuromuscular stimulators and electrical stimulation have been found 
to be very clinically effective in reducing the incidence of deep-vein thrombosis (Kaplan, 
Czyrny, Fung, Unsworth, & Hirsh, 2002; Browse & Negus, 1970; Lindström, Holmdahl, and 
Jonsson et al., 1982). However, the considered studies which involve direct electrical muscle 
stimulation do not necessarily lead to the adoption of effective and easy to use devices that 
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would enhance blood flow in the lower limb. The high intensity discomfort levels experienced 
by many patients who use the direct electrical stimulation devices to the muscle attribute to the 
high levels of failure to adopt Electrical stimulation. Their batteries for are irreplaceable and last 
slightly over 24 hour’s thus requiring daily replacement of the device. The cost of the devices, is 
approximately $20 USD and its daily replacement, is also a challenge to many low-income 
individuals. Such devices are often rather cumbersome, and may require chords, and they may be 
incompatible with use of a normal plaster cast or ambulation as is the case with Intermittent 
Pneumatic Compression (IPC) devices in edema management (Sluka & Walsh, 2003). Studies 
show that the electrical stimulation of the lower limb muscles is effective in improving the flow 
in the legs (Sluka et al., 2003). 
 
 
1.8 Geko
TM
 Device and Its Role in DVT Prevention and Lower Limb Edema 
 
Promoting venous blood flow is necessary in treatment of the leg edema but may it be 
difficult to conduct in patients with comorbidities through the use of traditional mechanical 
compression devices or limb elevation. The Geko
TM
 device is a self-powered neuromuscular 
stimulation device that is attached above the skin over the common peroneal nerve in the legs 
(Figure 3). Geko
TM
 device emits low-voltage that creates stimulus which in turn activates the 
lower limb musculature thus improving superficial femoral vein velocity and blood flow (Figure 
4). Chronic wound healing and pain reduction is also achieved through its use. Despite being 
expensive, Geko
TM
 has relatively welled toleration rates and can be used to provide alternative 
treatment for edema. The Geko
TM
 device has no known side effects when used according to 
instructions apart from minor skin irritation and rash. 
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Improving venous blood flow an effective method of treating leg edema and can be 
achieved through limb elevation irrespective of the etiology (Abu-Own A et al., 1994), activation 
of the leg’s calf muscle pump (Kan et al., 2001), regular ankle plantar flexion exercise (Padberg 
 
FT et al., 2004), and intermittent pneumatic compression (IPC) devices as well as other 
traditional mechanical devices like compression garments (O’Meara S et al., 2009). 
 
Unfortunately, patients suffering from contraindications to adequate compression such as 
peripheral arterial insufficiency, those having skin infections, as well as patients with comorbid 
conditions that limit movement of the legs cannot benefit from these treatment methods (Partsch 
et al., 2008). It is notable that current mechanical compression devices may induce discomfort in 
addition to their difficult application procedures which decreases compliance (Comerota AJ, 
2011) 
 
Transcutaneous direct muscular stimulation method can be used in treating edema by 
improving venous blood flow (Clarke et al., 2012). Transcutaneous direct muscular stimulation 
device promotes venous blood flow and stimulate the calf muscle pump by creating electrical 
stimulation by use of electrodes applied to the skin (Kaplan et al., 2002). However, results may 
vary in relation to voluntary ankle contraction (Breen PP et al., 2012). These devices are not 
popular in routine clinical use due to discomfort created by their high voltage. However, 
Geko
TM
 device has gained popularity as an alternative to direct electrical muscle stimulation 
(Tucker A et al., 2010). Geko
TM
 device delivers a low-voltage stimulus at a low frequency (1 
Hz), which activates the musculature of the legs with little discomfort. Additionally, it 
considerably increases blood flow and velocity in the superficial femoral vein (Breen PP et al., 
2012) while providing a possible tolerable and safe method for lower limb edema treatment. 
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The Geko
TM
 device is greatly advantageous over other stimulation devices due to its 
compactness, portability, ease of application, and an in-built power source lasting over 24hours. 
Its tolerability and potential clinical utility is well assessed in cohorts of healthy volunteers 
(Broderick BJ, 2010), including use by individuals wearing below-knee plaster casts, and has 
shown potential for use limited space conditions where other IPC devices fail to apply. 
 
 
 
1.8.1 Mechanism of Action of the Geko
TM
 Device 
 
Geko
TM
 device is a non-invasive On-Pulse™ technology powered device that works by 
stimulating patient’s calf muscles to increase blood circulation. It activates the muscle pumps of 
the lower limb through creating a small electrical impulse that in turn triggers the common 
peroneal nerve which improves pumping of blood in veins leading back to the heart. Geko
TM
 
device is a self-adhesive and well-designed device which can be wrapped around the leg, below 
the crease of the knee. It is ideal for person requiring reduction of blood stasis and increased 
circulation on the legs. The device improves the flow of blood while prevents venous thrombosis 
through direct post-surgical stimulation of the leg muscles. 
 
 
 
1.8.2 Benefits 
 
The device lowers venous thromboembolism risk by managing venous stasis. It also aids in good 
patient adherence due to the ease of application thus facilitating faster surgery patient recovery. 
Due to its comfort and ease of application, patient will retain their mobility and independence 
which ensures self-sufficiency and wellbeing. It observes minimum skin contact which reduces 
cases of skin breakdown, irritation, and unnecessary sweating. It delivers venous 
thromboembolism prophylaxis experience to patients who have a challenge in using the normal 
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venous thromboembolism prophylaxis. Its increased speed of patient recovery potential helps in 
eliminating lengthy hospital stay through reduction and prevention of subsequent complications 
such as edema (Broderick, O’Briain, Breen, Kearns, & Olaighin, 2010; Breen, Galvin, 
 
Quondamatteo, Grace, & ÓLaighin, 2012). 
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Figure 3: Geko
TM
 device (left), with the device in use on the right. Source: 
 
www.geko
TM
devices.com/enun/technology/specifications/neuromuscularstimulations-geko
tm
-t-1/ 
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Figure 4: Ultrasound comparison showing the superficial femoral vein at rest and with the 
device active at 1Hz. Source: www.geko
TM
devices.com/en-us/studies/neuromuscular-
electrostimulation-dvt-prophylaxis–nmes-studies-and-trials/blood-supply-augmentation-in-the-
leg/ 
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1.9 Rationale for the Proposed Study 
 
Numerous complications such as edema are associated with kidney and pancreas 
transplantation. Additionally, intermittent pneumatic compression devices (IPC) used in deep 
vein thrombosis and lymphedema treatments are not yet fully understood. However, their use is 
promoted by their undisputed hemodynamic effects. However, it is evident that IPC devices 
cause increase of velocity and volume of the venous flow through the femoral and/or popliteal 
veins. There is a further significant increase in the flow within the popliteal artery which has 
been previously reported while using IPC devices on patients suffering from critical limb 
ischemia. However, there are limitations of using the IPC device which include probable 
peroneal nerve injury, difficulty in fitting around the designated limb, inappropriate use of 
device, discomfort experienced by the patients, and unnecessary sweating and rise in temperature 
under the inflatable cuffs. Additionally, its weight, size, and external power source requirements 
and additional chord requirements contribute to poor comfort levels, acceptability, lack of proper 
compliance, and risk of falls which limits the efficacy of IPC devices. 
 
Electrical stimulation of the calf muscle pump has been proved to effectively and 
significantly reduce the perioperative and postoperative deep venous thrombosis (DVT) risk 
while simultaneously lowering the limb edema. Nevertheless, high currents applied to induce 
mechanical stimulation of the muscles leads to induction of pain which limits its practical use 
and reduces comfort. 
 
In this regard, a new improved, portable, easy to use, and internal-powered calf 
stimulator known as the Geko
TM
 device (Firstkind Ltd, Sky Medical Technology, and Cheshire, 
United Kingdom) was developed to address the problems of the traditional stimulators. It is 
comfortable, easy to apply and use and its reduced discomfort and pain improve patient 
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compliance and acceptance. Past hemodynamic research indicates that the device provides a 
significant increase in volume flow and velocity of blood and enhanced skin capillary blood 
flow. The significant increase in comfort, acceptability, and satisfaction level of patients, in 
addition to ease of use, enhance its preference and potential use in clinical settings such as 
kidney and pancreatic transplantation, where patients are prone to severe lower limb edema from 
the infusion of large volumes of fluid following transplantation. Edema management has 
traditionally been carried out by walking and workouts. However, challenges occur in cases of 
bedridden or minimally mobile patients where the natural, traditional therapy cannot apply. 
 
Although various studies have shown that the Geko 
TM
 device leads to an increase in 
flow of blood in the lower limbs equivalent to 60% of the levels which would be seen in 
continuous walking, no study has evaluated its efficacy compared to standard TEDS and SCD in 
transplantation. 
 
 
 
1.10 Aim of the Study 
 
The study aimed to examine the effect of Geko
TM
 device on post kidney and pancreatic 
transplantation leg edema. It was being conducted in a randomized controlled trial which 
involved kidney and pancreas transplant patients from the onset of the transplant through the 
recovery process. Patients were been randomized to one of the two groups; group 1: standard of 
care IPC and TED stockings to aid in blood circulation after the transplant, while group 2 will 
fitted with the Geko
TM
 device post-transplant. Various components of patient clinical outcomes 
and satisfaction were then evaluated and compared between the two groups. 
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1.11 Research Question 
 
The following research questions were posed in conducting the study: 
 
1. What is the effect of Geko
TM
 device on post kidney and pancreatic transplantation leg 
edema? 
 
2. What are the clinical outcomes observed between patients who receive routine medical 
therapy with IPC/TEDS versus the Geko
TM
 device? 
 
 
1.12 Hypothesis: 
 
We hypothesized that the use of the neuromuscular electric stimulation device (Geko
TM
) will 
achieve decreased lower limb edema, improved clinical outcomes and better patient satisfaction 
scores compared to standard IPC and TED stockings following transplantation. 
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Chapter 2 
 
2.1 Study Design and Methodology 
 
The current study employed a prospective, single-centered, controlled, and randomized 
investigator-initiated design in evaluating clinical outcomes on patients using either the Geko
TM
 
device or standard TEDS and SCD following kidney and kidney/pancreas transplantation. 
Patients were first supplied with written consent before being enrolled into the study and enrolled 
prior to the transplant operation and randomized to either treatment group (Figure 5). The 
randomization process is carried out by flipping a coin to ensure equal chances of placement 
within either group with those falling under the tail outcome being placed in the Geko
TM
 device 
group while those falling under the head outcome shifting to the IPC+TED group. Patients were 
assigned numbers, and the list stored in a centralized location in our research office indicating 
the assigned group of the patient. At the time of surgery, both groups of patients were placed on 
TEDs and SCD. On post-operative day 1, patients were placed in their assigned groups: patients 
randomized to the Geko
TM
 arm were fitted according to manufacturer’s instructions. If patients 
fell into the standard TEDS and SCD arm of the study, they were left earing them. However, if 
patients adversely responded to the Geko
TM
 device, they were transferred to the IPC+TED 
stockings group at the initial stage. The Geko
TM
 device was removed and replaced daily in 
patients. Both groups of patients were followed following surgery for six days after surgery on 
daily basis and at precisely the same time. Patients were normally discharged on the sixth day. 
 
The inclusion criteria for the study included patient’s written consent, age (where a 
patient should be above 18 years), and Body Mass Index (BMI) which should be between 18 and 
34. Additionally, the patients should be recipients undergoing either pancreas or kidney 
transplant, and there should be no known peripheral vascular ailments. 
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The exclusion criteria were as follows: age younger than 18 years, patients with history of deep 
vein thrombosis, contraindications to use of the device as listed on the manufacturer’s safety 
sheet, patients who have previously undergone leg amputation and patients with intra cardiac 
defibrillators. In addition to these, the patient could be excluded for having a BMI of more than 
36, possessing neurological disorder history or any ailment potentially hindering proper 
assessment, having presence of stimulators such as implantable brain, or inability to tolerate 
Geko
TM
 device stimulation. 
2.2 Ethics approval 
 
The research was approved by the University of Western Ontario Research Ethics Board. 
Every recruited patient was served with a written informed consent and made aware of freedom 
to withdraw from participation at any time and were assured that it would in no way affect the 
management or care they received. 
 
2.3 Primary and Secondary Endpoints 
 
2.3.1 Primary end points 
 
The primary intent of the study is to assess patients’ lower limb edema after surgery and 
patients` satisfaction with the Geko
TM
 device and IPC+TED stockings following transplantation. 
Measurements were made with a measuring tape whereby the thigh and calf circumference 
within 15cm above or below patella’s midpoint were evaluated in order to assess lower limb 
edema. The difference in circumference between the 1
st
 and 6
th
 days reflects lower limb edema 
assessment from admission to discharge day were recorded for further analysis. 
In regard to this assessment, 
 
 Change in circumference = difference in leg (below the knee) circumference 
between 1
st
 and 6
th
 days.
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  Difference in thigh circumference = difference between 1
st
 day and 6
th
 day thigh 
circumference (above the knee)
 
The following one page questionnaire was used to assess patient satisfaction with the use 
of the devices on the 6
th
 day post-transplant. There are six questions which relate to leg swelling, 
device comfort during the period, the intent to use the device in case of future surgeries, and the 
influence of the devices on mobility and sleep. 
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1. To which random group where you placed 
 
-IPC+TED stockings - Geko
TM
 Device (Check one) 
 
2. How comfortable are the devices 
 
- Extremely comfortable  
- Moderately comfortable  
- Average  
- Moderately uncomfortable  
- Extremely uncomfortable 
 
3. What is the extent of the leg swelling 
 
- Extremely increased  
- Slightly increased  
- No change  
- Slightly reduced  
- Extremely decreased 
 
4. What was the device’s influence on sleep patterns 
 
- Extremely positive  
- Moderately positive  
- No effect  
- Moderately negative  
- Extremely positive 
 
5. What is the device’s mobility after surgery 
 
- Extremely difficult  
- Moderately difficult  
- No change  
- Moderately easy  
- Extremely easy 
 
6. Would you want to use the same device if you had another surgery 
 
- Yes  
- No 
 
Table 2: Questionnaire to assess patient satisfaction with the use of the various devices. 
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 110 patients    
     
    
9 Patients excluded:     
    Neurogenic disease 
    (n=1) 
    History of DVT (n=2) 
    
Declined to participate  101 patients   
    
    (n=6) 
     
 
 
 
 
55 patients 
  
 
46 patients Geko IPC+TED  
  
   
   
 
 
 
5 KP 50 Kidneys 
42 Kidneys  4 KP 
 
 
Figure 5: Flow diagram of participants in the study. IPC: Intermittent Pneumatic 
Compression; TED: Thrombo-Embolic Deterrent; KP: Kidney and Pancreas; DVT: Deep 
Vein Thrombosis. 
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2.3.2 Secondary Endpoints: 
 
A number of secondary endpoints were carried out including assessing post-
transplantation weight by evaluating weight changes from day of admission through to discharge 
day. Every patient also underwent screening for subclinical deep-vein thrombosis (DVT) through 
ultrasound of the legs at the fifth day following transplantation. Total daily urine output was 
measured and recorded across every patient individually from transplant day to discharge day. 
Kidney functionality was assessed through serum creatinine and eGFR assessments at discharge 
day and at 21 days following transplantation. Doppler ultrasound was used to measure velocity at 
the femoral veins on day 5 post-transplant. Lastly, Doppler ultrasound was used to measure 
resistive index of transplanted kidneys at day one and five after transplant to evaluate whether or 
not there was an increase in renal capillary perfusion parameters with either technique. 
 
Of note, two actions occur to promote blood flow using the Intermittent Pneumatic 
Compression (IPC) by inflation and deflation. Inflation increases the pressure on the limb which 
forces blood and other fluids out the blood vessels towards to heart, whereas deflation lowers 
pressure on the leg which facilitates the refilling of the vascular fluids in the leg vessels. 
 
A Doppler ultrasound scan was conducted when the patient is not in motion and it 
revealed blood movement as a wave of peaks and troughs relative to the breathing pattern of the 
patient. Compilation of these scans and plotting them with the help of the built-in software gave 
us a pattern that was used to compute the average flow of blood during a particular duration by 
calculating the area under the curve. The IPC device takes about a minute to inflate and deflate 
which is too long for the instrument to make a single calculation over a single measurement. In 
this regard, two recordings were made with one being the flow of blood during inflation, labelled 
 
 
34 
 
F1, with the time it takes for the flow denoted as T1. The second recording which is in the 
opposite cycle involves measuring blood flow during deflation which is labelled F2 and the 
duration denoted T2. Summated values during the flow are obtained through making the 
following calculation: 
 
Total blood flow = {(T1/BT x F1)} + {(1-(T1/T2)) x F2} 
 
2.4 Statistical Analysis: 
 
GraphPad Software was used to conduct a statistic analysis using a Students’ T-test for 
independent groups where p< 0.05 representing the point of statistical significance. Additionally, 
all data in the following figures is reported as mean +/- standard deviation (SD). 
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Chapter 3 
 
3.1 Results 
 
The duration of recruitment took one year and involved a total of 101 patients. However, nine of 
the patients were excluded for failing the inclusion policy stated above. Of the excluded patients, 
one patient suffered from a neurological disorder; two had histories of venous thromboembolism, 
while six of them were not explicitly willing to participate in the study. 
Characteristic Intermittent   Compression Geko Device 
 Device + TED Stocking  
   
Number of Recipients 55 Patients 46 Patients 
   
Age (Years) 46.2±12 47.7±13 
   
Gender: Male 33 25 
Female 22 21 
   
Body Mass Index 26.2±4 25.4±6 
   
Weight 88.3±6 87.5±4 
   
Type of Dialysis: HD 41 37 
PD 10 4 
Preemptive 4 5 
   
Type of Surgery   
Kidney+Pancreatic 5 4 
Kidney 50 42 
   
 36  
Types of Donors    
LD 14  13 
NDD 26  19 
DCD 15  14 
    
Table 3: Patient characteristics. LD: Living donor; NDD: Neurological determination of death 
 
DCD: Donation after cardiac death; HD: Haemodialysis; PD: Peritoneal Dialysis. 
 
 
 
 
3.2 Primary End Point Results: 
 
3.2.1 Lower limb edema: 
 
Transplantation led to an overall increase in the circumference of the lower legs of both 
groups of patients due to significantly increased fluid administration. However, this increase was 
significantly greater in the IPC+TED stockings group by an average of 2.3 +/- 2.1 cm, whereas 
the Geko
TM
 group had an increase of 0.25 +/- 1.2 cm (p<0.001). Additionally, the thigh 
circumference increased by 2.5 +/- 2.3 cm in the IPC+TED stockings group and by 0.5 +/-0.8 cm 
in the Geko
TM
 groups (p<0.001), respectively (Figures 6 and 7). 
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Figure 6: Change in lower leg circumference following transplantation using IPC+TED or the 
Geko
TM
 device for 6 days following transplantation. Data are expressed as mean +/- standard 
deviation with *p<0.001. IPC: Intermittent Pneumatic Compression; TED: Thrombo-Embolic 
Deterrent. 
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Figure 7: Change in thigh circumference following transplantation using IPC+TED or the Geko 
 
TM
 device for 6 days following transplantation. Data are expressed as mean +/- standard 
deviation with *p<0.001. IPC: Intermittent Pneumatic Compression; TED: Thrombo-Embolic 
Deterrent. 
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3.2.2 Patient satisfaction: 
 
The answers from patients in both arms were recorded and presented as follows: 
 
Question 1: How comfortable are the devices? 
 
Of the 101 participants, 55 took part in the IPC+TED study while 46 were fitted with Geko
TM
 
device. When level of discomfort was evaluated in TED+IPC patients, 57% reported some level 
of discomfort, 29% reported no effect on comfort and 14% reported comfort. In contrast, the 
reports were skewed towards being more comfortable in the Geko
TM
 arm with 13%, 23%, and 
64%, being responses for discomfort, no effect on comfort, and comfortable, respectively. 
 
The Pearson Chi-square showed that there is a significant difference in comfortability between 
the two groups (P<0.003). 
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Figure 8: Comfort level following fitting of IPC+TED or the Geko 
TM
  device for 6 days post 
 
transplantation (P<0.003). IPC: Intermittent Pneumatic Compression; TED: Thrombo-Embolic 
 
Deterrent 
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Question 2: What is the extent of the leg swelling? 
 
When perception of leg swelling was evaluated, 52% of IPC+TED patients had an increase in leg 
swelling, 17% had no change, and 31% recorded a decrease in swelling while Geko
TM
 device 
participants recorded 22%, 30%, and 48%, respectively for the same questions. This suggests 
that patients who wore the Geko
TM
 device had the perception of improved leg edema compared 
to those patients who were on standard therapy. The Pearson Chi-square showed that there is a 
significant difference in the leg swelling between the two groups (P<0.001). 
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Figure 9: Extent of swelling following fitting of IPC+TED or the Geko 
TM
 device for 6 days 
post transplantation (P<0.001). IPC: Intermittent Pneumatic Compression; TED: Thrombo-
Embolic Deterrent. 
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Question 3. What was the device’s influence on sleep patterns? 
 
When asked about their sleep patterns, 49% of IPC+TED participants indicated no change in 
sleep patterns compared to 50% in the Geko
TM
 arm. However, 31% reported a negative change 
in the IPC+TED compared to only 16% in the Geko
TM
 group. Interestingly, 20% of patients 
reported that they had an easier time going to sleep in the IPC+TED group whereas this number 
was 34% in the Geko
TM
 arm. The Pearson Chi-square showed that there is a significant 
difference in device’s influence on sleep patterns between the two groups (P<0.02). 
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Figure 10: Influence on sleeping pattern following fitting of IPC+TED or the Geko 
TM
 device 
for 6 days post transplantation (P<0.02). IPC: Intermittent Pneumatic Compression; TED: 
Thrombo-Embolic Deterrent. 
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Question 4: What is the device’s mobility after surgery? 
 
After undergoing surgery, 29% of patients fitted with IPC+TED reported no effect on mobility 
while 28% and 43% reported difficulty and improvement in mobility, respectively. On the other 
hand, Geko
TM
 device created a 10% mobility difficulty with 17% reporting no change effect and 
73% reporting a free and improved mobility. This becomes increasingly important in patient 
mobility after major surgery and could have a significant impact on patient convalescence and 
length of stay in hospital. The Pearson Chi-square showed that there is a significant difference in 
mobility after surgery between the two groups (P<0.001). 
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Figure 11: mobility level following fitting of IPC+TED or the Geko 
TM
 device for 6 days post 
transplantation (P<0.001). IPC: Intermittent Pneumatic Compression; TED: Thrombo-Embolic 
Deterrent. 
 
 
 
 
 
 
 
 
 
 
 
 
47 
Question 5: Would you want to use the same device if you had another surgery? 
 
Interestingly, when asked about whether or not patients would like to use the same modality of 
treatment for another operation, only 57% of IPC+TED participants acknowledged that they 
would use it in comparison to Geko
TM
 device whose participants gave it 83%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Chances of future use of IPC+TED or the Geko 
TM
 device for 6 days post 
transplantation. IPC: Intermittent Pneumatic Compression; TED: Thrombo-Embolic Deterrent. 
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3.3 Secondary End Point Results: 
 
3.3.1 Femoral vein velocity: 
 
When we evaluated femoral vein velocity on day 5 following transplantation, we observed a 21 
+/- 7 cm/s mean femoral vein flow velocity in the IPC+TED arm. In comparison, we saw a 
significantly higher velocity in the Geko
TM
 group with a value of 28 +/- 8 cm/s (p<0.04, Figure 
13). 
3.3.2 Total urine output: 
 
Urine volume was collected and recorded daily for total of 6 days from the patients. The mean 
urine output being 8800 cc with a standard deviation of +/- 8 in the control arm in relation to 
17900 cc and a standard deviation of +/- 10 in the Geko
TM
 arm. There was statistically 
significant difference between the IPC+TED arm and Geko
TM
 arm (P<0.05, Figure 14). 
 
 
3.3.3 Measurement of intra-renal resistive index: 
 
We evaluated intrarenal resistive indices in the two groups to determine whether there would be 
a difference in renal perfusion. We found that neither on post-operative day 1 or on Day 5 was 
here an observable difference in the resistive index between the control arm and Geko
TM
 arm 
(Figures 15 and 16). 
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Figure 13: The flow velocity in femoral vein following transplantation using IPC+TED or the 
Geko
TM
 at day 5 following transplantation. Data are expressed as mean +/- standard deviation 
with *p<0.04. IPC: Intermittent Pneumatic Compression; TED: Thrombo-Embolic Deterrent. 
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*p<0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: The total urine output following transplantation using IPC+TED or the Geko
TM
 
device between 1
st
 and 6
th
 day following transplantation. Data are expressed as mean +/- 
standard deviation with *p<0.05. IPC: Intermittent Pneumatic Compression; TED: Thrombo-
Embolic Deterrent. 
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Figure 15: Resistive index following transplantation using IPC+TED or the Geko
TM
 device at 
day 1 following transplantation. Data are expressed as mean +/- standard deviation with p=0.69. 
IPC: Intermittent Pneumatic Compression; TED: Thrombo-Embolic Deterrent. 
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Figure 16: Resistive index following transplantation using IPC+TED or the Geko
TM
 device at 
day 5 following transplantation. Data are expressed as mean +/- standard deviation with p=0.69. 
IPC: Intermittent Pneumatic Compression; TED: Thrombo-Embolic Deterrent. 
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3.3.4 Weight change, kidney function, and subclinical DVT: 
 
Recordings were made concerning changes in weight after transplant, subclinical deep-
vein thrombosis (DVT) presence, and kidney functionality 6 and 21 days post transplantation. 
There was less weight gaining in the Geko
TM
 arm than the control arm (average weight change: 
+2.5 kg vs +6 kg) but it was not statistically significant (Figure17, p=0.09). 
 
There was a trend of lower creatinine level in the Geko
TM
 arm than the control arm at day 
6 in the DCD group (240±36.1 umol/l vs 270±29 umol/l), but it was not statistically significant. 
 
There was no difference in Estimated Glomerular filtration rate (eGFR) at the 6
th
 day 
between the control arm and Geko
TM
 arm (Figure 18, p=0.98). Also, there was no difference in 
eGFR after 21 days between the control arm and Geko
TM
 arm (Figure 19, P=0.97). There was 
no subclinical DVT in both IPC+TED group and Geko
TM
 group. 
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P=0.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: The weight difference between IPC+TED arm and Geko
TM
 arm. There was no 
statistical significance difference between the Geko
TM
 arm and the Control arm. Data are 
expressed as mean +/- standard deviation (p=0.09). IPC: Intermittent Pneumatic Compression; 
TED: Thrombo-Embolic Deterrent. 
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Figure 18: The eGFR at 6
th
 day between the control arm and Geko
TM
 arm. There was no 
statistical significance difference between the Geko
TM
 arm and the IPC+TED arm. Data are 
expressed as mean +/- standard deviation (p=0.97). IPC: Intermittent Pneumatic Compression; 
TED: Thrombo-Embolic Deterrent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: The eGFR 21 days after transplant in the control arm and Geko
TM
 arm. There was no 
statistical significance difference between the Geko
TM
 arm and the IPC+TE. Data are expressed 
as mean +/- standard deviation (p=0.96). IPC: Intermittent Pneumatic Compression; TED: 
Thrombo-Embolic Deterrent. 
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Chapter 4 
 
 
4. Discussion: 
 
 
The results of the current study are the first to show a direct comparison between standard 
IPC + TED treatment versus the Geko
TM
 device a novel technology adopting wearable 
neuromuscular stimulation in transplantation. We show, for the first time, that the use of the Geko
TM
 
device in the immediate postoperative setting following a kidney or kidney and pancreas transplant 
results in a significant reduction in lower leg and upper thigh circumference, increased urine output 
and a concomitant increase in femoral vein velocity suggestive of improved circulatory blood flow. It 
was noted that Geko
TM
 device improved led to increased venous blood velocity which signifies an 
improvement in blood circulation and consequently a rise blood flowing through various organs; 
including the renal, thus leading to the increase in urine output. In addition, we demonstrate that 
patients had much higher satisfaction scores wearing the Geko
TM
 device compared to the IPC+TED, 
especially in terms of improved comfort, perception of decreased edema, improved post-operative 
sleep hygiene, and enhanced early mobility. 
 
It was showed in the study that the creatinine is lesser at day six in the DCD group in the 
Geko
TM
 arm than the control arm, but it was not statistically significant. This result needs to be 
further studied with more powerful studies. 
 
The randomization of the patients and the balanced nature of the two groups with respect 
to gender whether or not the donor kidney was from a living or deceased donor all ensure to limit 
the bias in the reported findings. 
 
The present work demonstrates successful control and management of edema in complex 
surgery patients. Interestingly, the results were evident as early as 1-2 days after surgery and 
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definitely within six days of treatment commencement which was immediately after surgery. The 
 
Geko
TM
 device was also well tolerated with minimum recorded discomfort, immobility, and 
adverse effect on sleep. In operational matters, the devices work by stimulating muscles which 
promote the blood flow and consequently reducing the chances of edema and thrombosis which 
are rampant in transplant/surgery patients. This observation is supported by various studies that 
reveal improved blood flow in both limb blood vessels and consequently the other body organs. 
According to this research, Geko
TM
 device proves more successful than the IPC+TED stockings 
devices. Geko
TM
 device creates a direct muscular stimulation mechanism that promotes good 
blood flow to prevent edema. However, this method is much appropriate in preventing venous 
thrombosis by promoting flow of blood within the veins. Despite the absence of deep-vein 
thrombosis cases in this study, the muscle stimulants are known to act deep within the skin and 
help in improving action within blood veins of patients thus creating reducing chances and 
effects of deep-vein thrombosis. The other methods which involve nerve stimulation with no 
direct stimulation of the muscles act closer to the surface and, despite their history of pain 
reduction through action on sensory nerves; they prove lesser effective on such complex cases 
especially thrombosis-related ones. Although we did not notice any changes in rates of DVT 
between the two groups (we did not expect to see this effect due to the lower incidence of DVT 
in this population), we predict that in a larger cohort of patients, we may be able to tease out this 
effect. 
 
With regard to the changes in leg circumference, the recorded changes are positive and 
significantly better than those of the control with recorded increase in leg circumference for patients 
in the IPC +TED arm being higher than that of Geko
TM
 cohort. In reference to answer to the 
question on leg circumference change (Question 2), it is notable that the percentage under the 
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“Very increased” check box was 23% for IPC+TED against Geko’s 9%. Additionally, the 
percentage of Geko 
TM
 device’s patients who recorded large decreases in circumference was 
22% against IPC+TED’s 14%. With these significant differences between the two groups, it is 
clearly evident that the Geko
TM
 device may be an important contributor to patient recovery post 
transplantation. The relative positive changes recorded on patients fitted with the Geko
TM
 device 
was as a result of muscle and venous stimulation which improved flow of blood and 
consequently improved lymphatic drainage leading to a reduction in swelling. 
 
When patients undergo surgery or transplant (especially kidney and pancreas), they face 
the risk of swelling of their limbs as a result edema arising from buildup of body fluids. The 
cases are worse in patients whose bodies tend to reject the transplants. It is, therefore, necessary 
to conduct elaborate tests to ensure that patients are properly matched to their donors in order to 
reduce such cases. Additionally, thrombosis is known to occur in the blood vessels prompting 
swellings and pain in adverse cases as a result of the rise in blood pressure within the blood 
vessels. The Geko
TM
 device works as a stimulant to the muscle cells in areas where it is fitted 
which lead to improved results both at the immediate section and the other parts of the body as a 
result of the smooth flow of body fluids and the assistive aspect in muscle cells. The research 
outcomes demonstrate the positive changes that can be achieved with the correct application and 
monitoring of the device. 
 
Patients, especially those recovering from surgeries, are delicate and require good handling to 
guarantee their comfort and reduce any chances of interfering with the recuperation process. To 
validate the Geko
TM
 device’s appropriateness and effectiveness, it is necessary that the device has to 
pass the comfort test and preferably outperform the control set and other available devices. However, 
Geko
TM
 device had a cumulative positive comfort feedback of 64% against IPC+TED’s 
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 14%. Additionally, the discomfort percentage for Geko
TM
  device was 13% against IPC+TED’s 
 
57%. In this regard, Geko
TM
 device is designed to offer very high comfort levels of comfort to 
the patients. The device, therefore, proves that it is ideal for such sensitive and delicate cases 
involving vulnerable patients. This study further notes that the device has clear instructions on 
 
use which, coupled with the strictness in the experience and mandatory training of the staffs 
involved in the fitting and replacement process, assisted in realization of the satisfactory comfort 
 
levels. The edema challenge affects a huge section of the patients which means that any 
stimulating device with best results is a necessary factor in the recovery process. The comfort of 
 
these devices should be paramount to ensure that they appropriately solve the problem without 
necessarily creating further complications for the patients. 
 
The Geko
TM
 device recorded higher mobility rates which cumulated to 73% by adding the 
 
“somewhat easy” and “very easy” responses in relation to IPC+TED’s 43%. With discomfort 
patients accounting for 10%, this indicates that most of them could move easily without any 
 
negative effect from the device. The “very difficult” group accounted for 3% which quite a small 
number. The positive feedbacks realized in relation to effect on sleep pattern and future use in 
 
case of requirements (83% against 17%) indicate a high acceptability ration from the patients. 
This high positive feedback is congruent to the higher leg circumference reduction ratio which is 
 
a relief to the patients. The effect on sleep patterns and mobility was also seen to improve which 
is one of the attributes to the high acceptability ratio in cases of future requirement. Various 
 
studies support this outcome by showing both improvement in blood flow and a high patient 
satisfaction rate ((Tucker A et al., 2010); Breen PP et al., 2012; Broderick BJ, 2010). 
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With regard to the changes in leg circumference, the recorded changes are positive and 
way better than those of the control with recorded increase in leg circumference for patients 
under the IPC +TED being higher than that of Geko
TM
 plan. In reference to answer to the 
question on leg circumference change (Question 2), it is notable that the percentage under the 
 
“Very increased” check box was 23% for IPC+TED against Geko’s 9%. Additionally, the 
percentage of Geko
TM
 device’s patients who recorded huge decreases in circumference was 22% 
against IPC+TED’s 14%. With these huge differences, it is evidently clear. 
 
The above case study is a demonstration of successful control and management of edema in 
surgery patients. Interestingly, the results were evident within six days of treatment 
commencement which was immediately after surgery. The Geko
TM
 device was also well 
tolerated with minimum recorded discomfort, immobility, and adverse effect on sleep. In 
operational matters, the devices work by stimulating muscles which promote the blood flow and 
consequently reducing the chances of edema and thrombosis which are rampant in 
transplant/surgery patients. According to this research, Geko
TM
 device proves more successful 
than the IPC+TED stockings devices. Geko
TM
 device creates a direct muscular stimulation 
mechanism that promotes good blood flow to prevent edema. However, this method is much 
appropriate in preventing venous thrombosis by promoting flow of blood within the veins. 
Despite the absence of deep-vein thrombosis cases in this study, the muscle stimulants are 
known to act deep within the skin and help in improving action within blood veins of patients 
thus creating reducing chances and effects of deep-vein thrombosis. The other methods which 
involve nerve stimulation with no direct stimulation of the muscles act closer to the surface and, 
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despite their history of pain reduction through action on sensory nerves; they prove lesser 
effective on such complex cases especially thrombosis-related ones. 
 
In reference to the physical nature and patient satisfaction, the Geko device is lightweight 
and requires no additional power connections as it is self-powered. Its battery power is sufficient 
to maintain it for the 24-hour stipulation period. 
 
This study followed clearly set guidelines in delivering its results. As with every other 
research, however, the study leaves room for future and further studies. The guidelines included 
an inclusion and exclusion clause that excluded patients who had known past complications such 
skin problems, ECG electrode requirement, hematological disorders, BMI index ratings 
exceeding 36, and leg amputation among others. 
 
Limitations of the Study 
 
 
The results achieved, and the conclusion deduced are only valid for patients who match 
the medical aspects of the inclusion criteria. Therefore, this calls for future research which 
should address the groups not covered in this section. Additionally, there is a necessity to address 
the compatibility of Geko
TM
 device with patients using brain stimulators and the effect that it can 
pause to such patients. Despite its high acceptability ratio, it is necessary to address the small 
percentage reporting adverse issues to ensure that patients have equal chances of benefiting from 
the device since, as derived above; it possesses excellent benefits on patients on post kidney and 
pancreatic transplant and leg edema patients. 
 
Notably, Geko
TM
 device requires daily replacement on patients. The cost of replacing the 
device on a daily basis further increases its costs, and it might prove too expensive to afford for 
patients especially from the low-income backgrounds. In order to ensure exhaustive results, 
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complete acceptability, and utilize all its beneficial aspects as evaluated within the research 
findings, there is a necessity to include the economic variable in future research. 
 
Lastly, although the numbers in each group are matched, there are subgroups within each 
of our categories including various types of donor populations which may be important to tease 
out when considering the data. For the purposes of our study, these were grouped together when 
 
evaluating the final data, however, it was evident from our subgroup evaluation that the DCD 
group may benefit to a greater extent from the Geko
TM
 device in turns of early urine output and 
 
edema, however the numbers are too small to make any concrete inferences. These subgroup 
evaluations should be carried out in larger cohorts. 
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